We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$849M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+44.51%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$290M
AUM Growth
+$54.7M
(+23%)
Cap. Flow
+$19M
Cap. Flow
% of AUM
6.54%
Top 10 Holdings %
Top 10 Hldgs %
36.73%
Holding
98
New
24
Increased
37
Reduced
19
Closed
12
Top Buys
| 1 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
+$9.42M |
| 2 |
Nuvalent
NUVL
|
+$7.29M |
| 3 |
Biogen
BIIB
|
+$6.21M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
+$4.88M |
| 5 |
TERN
Terns Pharmaceuticals
TERN
|
+$4.56M |
Top Sells
| 1 |
Veracyte
VCYT
|
+$10.8M |
| 2 |
APEN
Apollo Endosurgery, Inc.
APEN
|
+$6.26M |
| 3 |
AKRO
Akero Therapeutics
AKRO
|
+$5.48M |
| 4 |
Cogent Biosciences
COGT
|
+$5.3M |
| 5 |
Nkarta
NKTX
|
+$4.77M |
Sector Composition
| 1 | Healthcare | 96.19% |
| 2 | Technology | 0.09% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Madrigal Pharmaceuticals
MDGL
$12.4B
| $14.5M | 4.99% |
+49,898
| New | +$4.88M |
|
|
BLU
2
DELISTED
BELLUS Health Inc.
BLU
| $14M | 4.83% |
1,707,370
+51,595
| +3% | +$481K |
|
|
PSTX
3
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $11.8M | 4.07% |
2,230,000
-324,277
| -13% | -$1.48M |
|
|
VRAY
4
DELISTED
ViewRay, Inc.
VRAY
| $10.8M | 3.71% |
2,405,360
+81,294
| +3% | +$354K |
|
5
Xenon Pharmaceuticals
XENE
$6.51B
| $10M | 3.44% |
253,655
+7,663
| +3% | +$279K |
|
|
AKRO
6
DELISTED
Akero Therapeutics
AKRO
| $9.43M | 3.25% |
172,100
-127,900
| -43% | -$5.48M |
|
7
Immunovant
IMVT
$7.96B
| $9.22M | 3.18% |
519,614
+219,614
| +73% | +$2.77M |
|
|
8
Nuvalent
NUVL
$9.81B
| $9.02M | 3.11% |
302,963
+261,524
| +631% | +$7.29M |
|
|
MORF
9
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $8.95M | 3.08% |
334,535
+10,114
| +3% | +$276K |
|
10
Alnylam Pharmaceuticals
ALNY
$37.6B
| $8.95M | 3.08% |
37,652
+5,107
| +16% | +$1.09M |
|
|
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $7.43M | 2.56% |
140,366
+4,240
| +3% | +$212K |
|
12
Oric Pharmaceuticals
ORIC
$1.09B
| $7.28M | 2.51% |
1,236,296
+27,304
| +2% | +$92.2K |
|
|
TERN
13
DELISTED
Terns Pharmaceuticals
TERN
| $7.13M | 2.45% |
700,000
+685,527
| +4,737% | +$4.56M |
|
|
MRSN
14
DELISTED
Mersana Therapeutics
MRSN
| $6.68M | 2.3% |
45,607
+5,844
| +15% | +$988K |
|
|
15
Biogen
BIIB
$28.3B
| $6.09M | 2.1% |
+21,975
| New | +$6.21M |
|
16
Cerus
CERS
$615M
| $5.96M | 2.05% |
1,634,014
+17,555
| +1% | +$66.2K |
|
17
CVRx
CVRX
$137M
| $5.77M | 1.99% |
314,584
+6,664
| +2% | +$82.2K |
|
18
Aclaris Therapeutics
ACRS
$758M
| $5.55M | 1.91% |
352,193
-191,583
| -35% | -$3.08M |
|
|
RXDX
19
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $5.5M | 1.89% |
+50,000
| New | +$3.24M |
|
|
CINC
20
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $4.86M | 1.67% |
+395,382
| New | +$9.42M |
|
21
GSK
GSK
$103B
| $4.79M | 1.65% |
+136,178
| New | +$4.54M |
|
|
22
Veracyte
VCYT
$4.52B
| $4.75M | 1.63% |
200,000
-465,854
| -70% | -$10.8M |
|
23
Krystal Biotech
KRYS
$10B
| $4.64M | 1.6% |
58,535
+1,890
| +3% | +$140K |
|
24
BioAtla
BCAB
$6.74M
| $4.51M | 1.55% |
10,938
+6,930
| +173% | +$2.88M |
|
25
United Therapeutics
UTHR
$22.4B
| $4.46M | 1.54% |
16,048
+5,352
| +50% | +$1.35M |
|
Similar funds
BOTOTLSJU
EFG
LA
EPIMS
CFP
USAA
OMC
AIA